PHIO
Income statement / Annual
Last year (2025), Phio Pharmaceuticals Corp's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Phio Pharmaceuticals Corp's net income was -$8.70 M.
See Phio Pharmaceuticals Corp,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$21.00 K |
$138.00 K |
$15.00 K |
$19.00 K |
| Cost of Revenue |
$0.00
|
$3.64 M
|
$6.33 M
|
$7.01 M
|
$8.89 M
|
$3.72 M
|
$0.00
|
$4.33 M
|
$5.37 M
|
$5.42 M
|
| Gross Profit |
$0.00
|
-$3.64 M
|
-$6.33 M
|
-$7.01 M
|
-$8.89 M
|
-$3.72 M
|
$21.00 K
|
-$4.19 M
|
-$5.36 M
|
-$5.40 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
-30.35
|
-357
|
-284
|
| Research and Development Expenses |
$4.62 M
|
$3.64 M
|
$6.33 M
|
$7.01 M
|
$8.89 M
|
$3.72 M
|
$4.30 M
|
$4.33 M
|
$5.37 M
|
$5.42 M
|
| General & Administrative Expenses |
$4.60 M
|
$3.74 M
|
$4.29 M
|
$4.45 M
|
$4.63 M
|
$5.08 M
|
$4.71 M
|
$3.18 M
|
$4.01 M
|
$3.62 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.60 M
|
$3.74 M
|
$4.29 M
|
$4.45 M
|
$4.63 M
|
$5.08 M
|
$4.71 M
|
$3.18 M
|
$4.01 M
|
$3.62 M
|
| Other Expenses |
$0.00
|
-$3.64 M
|
-$6.13 M
|
-$7.01 M
|
-$8.89 M
|
-$3.72 M
|
$0.00
|
$4.00 K
|
$4.70 M
|
$3.11 M
|
| Operating Expenses |
$9.22 M
|
$3.74 M
|
$4.49 M
|
$4.45 M
|
$4.63 M
|
$5.08 M
|
$9.01 M
|
$7.50 M
|
$9.38 M
|
$9.03 M
|
| Cost And Expenses |
$9.22 M
|
$7.39 M
|
$10.82 M
|
$11.46 M
|
$13.51 M
|
$8.79 M
|
$9.01 M
|
$7.50 M
|
$9.38 M
|
$9.03 M
|
| Interest Income |
$0.00
|
$231.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$15.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.00 K
|
$0.00
|
| Depreciation & Amortization |
$3.00 K
|
$2.00 K
|
$184.00 K
|
$71.00 K
|
$75.00 K
|
$72.00 K
|
$67.00 K
|
$81.00 K
|
$70.00 K
|
$53.00 K
|
| EBITDA |
-$8.70 M |
-$7.15 M |
-$10.64 M |
-$11.41 M |
-$13.21 M |
-$8.72 M |
-$8.92 M |
-$7.28 M |
-$14.00 M |
-$8.96 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-424.76
|
-52.78
|
-933.53
|
-471.68
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-427.95
|
-53.36
|
-937.47
|
-474.47
|
| Total Other Income/Expenses Net |
$522.00 K
|
$237.00 K
|
-$2.00 K
|
-$18.00 K
|
$224.00 K
|
-$1.00 K
|
$79.00 K
|
$4.00 K
|
-$11.00 K
|
$21.00 K
|
| Income Before Tax |
-$8.70 M
|
-$7.15 M
|
-$10.83 M
|
-$11.48 M
|
-$13.29 M
|
-$8.79 M
|
-$8.91 M
|
-$7.36 M
|
-$14.07 M
|
-$8.99 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-424.19
|
-53.33
|
-938.2
|
-473.37
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4.00 K
|
-$1.62 M
|
-$74.00 K
|
| Net Income |
-$8.70 M
|
-$7.15 M
|
-$10.83 M
|
-$11.48 M
|
-$13.29 M
|
-$8.79 M
|
-$8.91 M
|
-$7.36 M
|
-$12.45 M
|
-$8.99 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-424.19
|
-53.33
|
-830.13
|
-473.37
|
| EPS |
-1.45 |
-0.91 |
-46.87 |
-89.61 |
-111.32 |
-207.25 |
-2074.18 |
-6218.35 |
-32801.22 |
-79282.81 |
| EPS Diluted |
-1.45 |
-0.91 |
-46.76 |
-89.61 |
-111.32 |
-207.25 |
-2074.18 |
-6218.35 |
-32801.22 |
-79282.81 |
| Weighted Average Shares Out |
$5.98 M
|
$787.47 K
|
$231.00 K
|
$126.16 K
|
$118.68 K
|
$42.43 K
|
$4.26 K
|
$1.18 K
|
$379.62
|
$113.44
|
| Weighted Average Shares Out Diluted |
$5.98 M
|
$787.47 K
|
$231.51 K
|
$126.16 K
|
$118.68 K
|
$42.43 K
|
$4.26 K
|
$1.18 K
|
$379.62
|
$113.44
|
| Link |
|
|
|
|
|
|
|
|
|
|
